Two Studies Evaluate EO2 Concepts' Oxygen Delivery System for Wound Healing

September 28, 2018—EO2 Concepts announced the publication of two studies supporting the company's wearable EO2 oxygen delivery system for wound healing. Mark Q. Niederauer, PhD, who is Chief Technology & Operations Officer of EO2 Concepts, presented the results of both studies at the Fourth International Skin Integrity and Infection Conference held September 14 in Las Vegas, Nevada.

The EO2 system continuously delivers and monitors the delivery of consistent, precise levels of pure, humidified oxygen to bring wounds to full closure. The system also works under direct compression. The EO2 system is commercially available in the United States, Canada, Europe, and the Middle East.

In Journal of Wound Care, Dr. Niederauer et al published findings from a randomized, double-blind, multicenter study of the EO2 system in patients undergoing treatment for diabetic foot ulcers with continuous diffusion of oxygen (CDO) therapy. The company stated that the study provides level I clinical evidence for the treatment of chronic wounds.

According to the company, the results demonstrated significant improvements in the primary outcome of complete wound closure at 12 weeks with CDO therapy over the current standard of care using a placebo device. The CDO arm performed 195% better and the time to ulcer closure was significantly shorter compared to the placebo arm. Furthermore, patients with more complex wounds were more than three times more likely to experience complete wound closure with CDO treatment versus the standard of wound care alone.

In the company's announcement, Dr. Niederauer commented, "These outstanding results demonstrate that CDO therapy with the EO2 system substantially improves the healing process in chronic wounds by providing faster, complete healing, particularly in patients with more complex wounds. These results have the potential to change the standard of care for chronic wound management going forward."

In Wound Central, Joanne Bowen, RN, et al published results of a 20-patient study that evaluated the effectiveness and the pain-reduction properties of the EO2 system. CDO was found to reduce pain in all patients, and rapidly reduce pain in most patients, with some reporting complete pain relief within hours of application. The investigators concluded that the reduction in pain may improve patient compliance and curtail the overuse of medications, such as opioids, prescribed to patients with chronic wound pain, reported EO2 Concepts.